Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. DXCM
stocks logo

DXCM

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
1.24B
+11.55%
0.647
+43.84%
1.18B
+13.8%
0.475
+48.35%
1.29B
+11.83%
0.593
+23.63%
Estimates Revision
The market is revising Upward the revenue expectations for DexCom, Inc. (DXCM) for FY2025, with the revenue forecasts being adjusted by 0.44% over the past three months. During the same period, the stock price has changed by -18.95%.
Revenue Estimates for FY2025
Revise Upward
up Image
+0.44%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
up Image
+0.73%
In Past 3 Month
Stock Price
Go Down
down Image
-18.95%
In Past 3 Month
Wall Street analysts forecast DXCM stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for DXCM is 85.75 USD with a low forecast of 63.00 USD and a high forecast of 112.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
22 Analyst Rating
Wall Street analysts forecast DXCM stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for DXCM is 85.75 USD with a low forecast of 63.00 USD and a high forecast of 112.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
17 Buy
5 Hold
0 Sell
Strong Buy
Current: 65.250
sliders
Low
63.00
Averages
85.75
High
112.00
Current: 65.250
sliders
Low
63.00
Averages
85.75
High
112.00
Morgan Stanley
Patrick Wood
Equal Weight
to
Overweight
upgrade
$75
2025-12-02
New
Reason
Morgan Stanley
Patrick Wood
Price Target
$75
2025-12-02
New
upgrade
Equal Weight
to
Overweight
Reason
Morgan Stanley analyst Patrick Wood upgraded DexCom to Overweight from Equal Weight with a $75 price target.
Morgan Stanley
Morgan Stanley
Equal Weight -> Overweight
upgrade
$63 -> $75
2025-12-02
New
Reason
Morgan Stanley
Morgan Stanley
Price Target
$63 -> $75
2025-12-02
New
upgrade
Equal Weight -> Overweight
Reason
As previously reported, Morgan Stanley upgraded DexCom to Overweight from Equal Weight with a price target of $75, up from $63, citing signs that the company is already turning the corner from a number of operational challenges while valuation remains at trough levels. The firm expects this turn to become apparent in the full results due in January or February, adding that it believes the G7 15-day rollout's impact on margins in the year ahead is "underappreciated" and it expects the stock to re-rate as catalysts play out.
BofA
analyst
Buy
maintain
$10
2025-11-25
Reason
BofA
analyst
Price Target
$10
2025-11-25
maintain
Buy
Reason
After the Office of Inspector General report on Medicare payments for continuous glucose monitors and supplies came out, BofA noted that the report is just the OIG's recommendation to CMS and is not an update to the CMS proposal regarding competitive bidding from July. With that said, the firm views the OIG report positively for DexCom as it shows Class 2 supplies are priced fairly to in line with Medicare expectations, adds the analyst, who maintains a Buy rating and $10 price target on the shares.
Evercore ISI
In Line
initiated
$68
2025-11-25
Reason
Evercore ISI
Price Target
$68
2025-11-25
initiated
In Line
Reason
Evercore ISI initiated coverage of DexCom with an In Line rating and $68 price target. Though DexCom serves the "large and vastly underpenetrated" diabetes market, the firm's In Line rating reflects its belief that product quality and manufacturing issues and competitive threats will continue to disrupt the company's share gain opportunity through 2026, the analyst tells investors.
Morgan Stanley
Overweight
downgrade
$89 -> $63
2025-11-10
Reason
Morgan Stanley
Price Target
$89 -> $63
2025-11-10
downgrade
Overweight
Reason
Morgan Stanley lowered the firm's price target on DexCom to $63 from $89 and keeps an Overweight rating on the shares.
UBS
Buy
downgrade
$106 -> $95
2025-11-03
Reason
UBS
Price Target
$106 -> $95
2025-11-03
downgrade
Buy
Reason
UBS lowered the firm's price target on DexCom to $95 from $106 and keeps a Buy rating on the shares. DexCom's solid sales beat overshadowed by margin weakness, but the firm remains confident in a sustainable mid-to-high teens sales growth outlook, the analyst tells investors in a research note.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Dexcom Inc (DXCM.O) is 27.32, compared to its 5-year average forward P/E of 90.57. For a more detailed relative valuation and DCF analysis to assess Dexcom Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Undervalued
5Y Average PE
90.57
Current PE
27.32
Overvalued PE
138.19
Undervalued PE
42.94

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
47.16
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
72.67
Undervalued EV/EBITDA
21.65

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
11.46
Current PS
0.00
Overvalued PS
15.54
Undervalued PS
7.39
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders areSelling! The selling amount has increased 161.76% over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders areSelling! The selling amount has increased 161.76% over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

DXCM News & Events

Events Timeline

(ET)
2025-11-03
09:55:01
Significant Early Gainers in Liquid Options on November 3rd
select
2025-10-31 (ET)
2025-10-31
08:51:29
Video: Apple and Amazon Drive Market Recovery
select
link
2025-10-30 (ET)
2025-10-30
16:07:04
DexCom projects FY25 revenue between $4.63B and $4.65B, surpassing consensus of $4.62B
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
7.0
07:22 AMGlobenewswire
DexCom Faces Class Action Over G6 and G7 Device Issues
  • Legal Action Initiated: DexCom, Inc. is facing a class action lawsuit for failing to disclose unauthorized design changes to its G6 and G7 devices between January 8, 2024, and September 17, 2025, which could expose the company to significant legal and financial risks.
  • Health Risk Warning: The lawsuit alleges that DexCom did not disclose that these design changes rendered the G6 and G7 devices less reliable, posing substantial health risks to users relying on these devices, which could impact user trust and market share.
  • Increased Regulatory Pressure: Due to the undisclosed design issues, DexCom may face heightened regulatory scrutiny and enforcement actions, increasing pressure on the company in terms of compliance and operations, potentially affecting future business development.
  • Investor Losses: The Wildermuth Fund class action alleges that from November 1, 2020, to June 29, 2023, miscalculations of fair value led to investor losses, which could damage the fund's reputation and investor confidence.
[object Object]
Preview
8.0
12-04NASDAQ.COM
DexCom (DXCM) Offers January 2026 Options

  • Put Contract Overview: The $57.00 put contract for DXCM has a bid of $1.00, allowing investors to buy shares at a reduced cost basis of $56.00, which is an 11% discount from the current price of $64.19. There is a 76% chance the contract may expire worthless, offering a potential 1.75% return on cash commitment.

  • Call Contract Overview: The $70.00 call contract has a bid of $1.60, enabling investors to sell shares at that price while collecting the premium. This could yield an 11.54% return if the stock is called away, with a 63% chance of the contract expiring worthless, resulting in a 2.49% additional return.

  • Volatility Insights: The implied volatility for the put contract is 57%, while for the call contract it is 51%. The actual trailing twelve-month volatility is calculated at 45%, indicating a lower actual volatility compared to the implied figures.

  • YieldBoost Concept: Both the put and call contracts offer potential YieldBoosts, with the put providing a 12.81% annualized return if it expires worthless, and the call offering an 18.20% annualized return under similar conditions.

[object Object]
Preview
3.5
12-04Newsfilter
Dexcom Launches Personalized Learning Platform to Enhance HCP CGM Knowledge
  • Platform Launch: Dexcom has launched Dexcom Academy, a personalized learning platform aimed at enhancing healthcare professionals' confidence in continuous glucose monitoring (CGM), now available in Belgium, Germany, Saudi Arabia, the Netherlands, and Spain, with further expansion planned across EMEA by 2026.
  • Responding to Educational Needs: According to a Dexcom survey, 38% of healthcare professionals believe ongoing education is crucial for addressing challenges in caring for type 2 diabetes patients, and Dexcom Academy directly meets this need by providing flexible, personalized learning modules.
  • Rich Learning Content: The platform offers training on Dexcom G7 and Dexcom ONE+, along with practical case studies based on real clinical scenarios, enabling healthcare professionals to apply their learning immediately in consultations, thereby enhancing patient care quality.
  • Long-term Commitment: Dexcom Academy reflects the company's ongoing investment in product excellence and education, with plans to continue launching high-quality CGM training across EMEA to adapt to evolving clinical needs.
Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Dexcom Inc (DXCM) stock price today?

The current price of DXCM is 65.25 USD — it has increased 0.62 % in the last trading day.

arrow icon

What is Dexcom Inc (DXCM)'s business?

DexCom, Inc. is a medical device company. The Company is primarily focused on the design, development, and commercialization of continuous glucose monitoring (CGM), systems for the management of diabetes and metabolic health by patients, caregivers, and clinicians. Its products include Dexcom G6, Dexcom G7, Stelo, Dexcom Share, and Dexcom ONE. The Company enables people to take control of health through innovative biosensing technology. Dexcom G6 is its integrated continuous glucose monitoring system (iCGM). Stelo is designed specifically for people with type II diabetes who do not use insulin as the first over-the-counter glucose biosensor in the United States. The Dexcom Share remote monitoring system, offered for use with any Dexcom system, uses an app on the patient’s compatible mobile device. Its Dexcom G7 is for adults and children (2+ years) living with type I or type II diabetes who are on any insulin or medications, at risk of hypoglycemia, and those with gestational diabetes.

arrow icon

What is the price predicton of DXCM Stock?

Wall Street analysts forecast DXCM stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for DXCM is 85.75 USD with a low forecast of 63.00 USD and a high forecast of 112.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Dexcom Inc (DXCM)'s revenue for the last quarter?

Dexcom Inc revenue for the last quarter amounts to 1.21B USD, increased 21.64 % YoY.

arrow icon

What is Dexcom Inc (DXCM)'s earnings per share (EPS) for the last quarter?

Dexcom Inc. EPS for the last quarter amounts to 0.70 USD, increased 112.12 % YoY.

arrow icon

What changes have occurred in the market's expectations for Dexcom Inc (DXCM)'s fundamentals?

The market is revising Upward the revenue expectations for DexCom, Inc. (DXCM) for FY2025, with the revenue forecasts being adjusted by 0.44% over the past three months. During the same period, the stock price has changed by -18.95%.
arrow icon

How many employees does Dexcom Inc (DXCM). have?

Dexcom Inc (DXCM) has 10300 emplpoyees as of December 05 2025.

arrow icon

What is Dexcom Inc (DXCM) market cap?

Today DXCM has the market capitalization of 25.45B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free